摘要
目的观察葛根素对脑缺血再灌注大鼠海马组织中Bcl-2、Beclin1及LC3表达的影响。方法 28只雄性SD(250~300g)大鼠随机分为假手术组、模型组、葛根素低剂量(50mg/kg)组和葛根素高剂量(100mg/kg)组。连续给药7 d,末次给药1 h后,建立大脑中动脉闭塞模型,缺血90 min后,再灌注24 h,评估神经功能,采用TTC染色观察脑梗死面积,Western Blotting法检测缺血侧海马组织中Bcl-2、Beclin1及LC3蛋白表达的变化。结果与假手术组比较,模型组的大鼠神经功能损伤显著增强,脑梗死面积增加,Bcl-2蛋白表达显著下调,Beclin1蛋白表达显著上调,LC3-II/LC3-I的比值显著上升;与模型组比较,葛根素低、高剂量组随着剂量的增加,大鼠的神经功能损伤逐渐改善,脑梗死面积逐渐减小,Bcl-2的表达逐渐上调,Beclin1的表达逐渐下调,LC3-II/LC3-I的比值逐渐下降,呈剂量依赖性。结论葛根素可通过调控脑缺血/再灌注后凋亡基因Bcl-2的表达,下调自噬相关蛋白Beclin1及LC3蛋白表达,抑制过度自噬,继而达到保护缺血性中风损伤的目的。
Objective To observe effects of puerarin on the expression of Beclin1、Bcl-2 and LC3 proteins in the hippocampal tissue of rats with cerebral ischemia-reperfusion injury. Methods Male Sprague-Dawley( SD)( 250-300 g) rats were randomly divided into: sham group,model group,low-dose puerarin group( 50 mg/kg),high-dose puerarin group( 100 mg/kg). After 7 days pretreatment,the middle cerebral artery occlusion( MCAO) model was established 1 h after the last administration according to Longa's method. After 90 min MCAO and 24 h reperfusion,the neurological deficit scores were assessed,the infarct volume was calculated by 2,3,5-triphenyltetrazolium chloride( TTC) staining and the expressions of Bcl-2,Beclin1 and LC3 were detected by Western Blotting. Results Compared with the rats in the sham group,the model group rats' neurological deficit scores,infarct volume,the expression of Bcl-2 was significantly enhanced,while Beclin1 and LC3-II/LC3-I expressions,remarkably reduced. Compared with the model group,as the dose of puerarin increased,the neurological impairment of rats gradually improved,the area of cerebral infarction gradually decreased,the expression of Bcl-2 gradually increased,the expression of Beclin1 and LC3-II/LC3-I gradually decreased,and in a dose-dependent manner. Conclusion Puerarin can alleviate excessive autophagy by regulating the expression of Bcl-2,Beclin1 and LC3 proteins after cerebral ischemia/reperfusion,and then protect against ischemic stroke injury.
作者
王静静
梅志刚
汪露
刘晓露
程瑶
冯知涛
张继红
谭凌菁
WANG Jing-jing;MEI zhi-gang;WANG Lu;LIU Xiao-lu;CHENG Yao;FENG zhi-tao;ZHANG Ji-hong;TAN Ling-jing(Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Tradi-tional Chinese Medicine,Medical College of China Three Gorges University,Yichang 443002,China;Second People's Hospital of Three Gorges University,Yichang 443000,China)
出处
《时珍国医国药》
CAS
CSCD
北大核心
2018年第5期1064-1068,共5页
Lishizhen Medicine and Materia Medica Research
基金
国家自然科学基金(81202625)
缺血性心脑疾病转化医学重点实验室(三峡大学)开放基金项目(2016xnxg101)